The Federal Trade Commission’s data-security trial against LabMD is in disarray after the House Oversight Committee sent a letter to the agency warning that a key witness provided information that is “incomplete and inaccurate” and “may not have been truthful.”
On June 11, committee chairman Darrell Issa, R-Calif., wrote to FTC Chairwoman Edith Ramirez, casting doubt on information that cybersecurity company Tiversa Inc. provided to the FTC about LabMD’s data breach.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
